WebJan 28, 2015 · Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally. The study duration is approximately 18 … WebSolithera™ (solithromycin, CEM-101) has successfully completed two Phase 3 clinical trials for community acquired bacterial pneumonia (CABP) and applications for approval for …
solithromycin « New Drug Approvals
WebAug 19, 2015 · These incentives include FDA priority review, eligibility for fast-track status and, if ultimately approved by the FDA, solithromycin would be eligible for an additional five-year extension of Hatch-Waxman new chemical entity exclusivity. About Cempra, Inc. WebAug 7, 2016 · Solithera (solithromycin) is a next-generation macrolide antibiotic developed by Cempra as a treatment for community-acquired bacterial pneumonia. Two new drug … on sale service
Solithromycin - Wikipedia
WebSolithromycin also appears to possess activity against pathogens resistant to earlier ketolides, such as telithromycin and cethromycin (ABT-773), a new agent in phase III … WebJun 13, 2013 · The FDA provided comments on the Phase 3 oral CABP protocol in June, 2012, and this global study is ongoing. This study compares five days of oral solithromycin with seven days of oral moxifloxacin. FDA responses prior to and at the End-of-Phase 2 meeting addressed the second Phase 3 study, which is the planned intravenous-to-oral … WebThe FDA has rejected approval of Cempra’s Solithromycin due to its risks. If you are a victim of a bad drug, call The Eichholz Law Firm in GA. ... is an unmet medical need for new … in your eyes benson produttore